- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07627945
Natural Enzyme Mouthwash After Third Molar Surgery
The Effects of Natural Enzyme-Containing Mouthwash in Wound Healing After Surgical Removal of Impacted Mandibular Third Molar
This clinical study investigates whether a natural enzyme-containing mouthwash (ORAL7®) can improve healing, pain and mouth opening after the surgical removal of impacted lower wisdom teeth (mandibular third molars), compared to a commonly used antiseptic mouthwash (0.2% chlorhexidine gluconate).
Wisdom tooth removal is a routine dental surgery, but it can lead to common postoperative problems such as pain, swelling, difficulty in opening the mouth, and delayed healing of the surgical wound. After surgery, patients are usually advised to use an antiseptic mouthwash to reduce bacteria in the mouth and support healing. Chlorhexidine mouthwash is widely used for this purpose, but it may cause side effects such as tooth staining, taste disturbance, and irritation in some patients.
ORAL7® is a newer type of mouthwash that contains natural enzymes similar to those found in saliva, including lactoperoxidase, lysozyme, lactoferrin, and glucose oxidase. These enzymes help the mouth's natural defense system by reducing harmful bacteria, controlling inflammation, and supporting tissue repair. Because of these properties, ORAL7® may offer a gentler alternative to chlorhexidine while still promoting good healing.
The study will involve patients undergoing surgical removal of impacted lower wisdom teeth. After surgery, participants will be randomly assigned to use either ORAL7® mouthwash or 0.2% chlorhexidine mouthwash for one week. Neither group will know which mouthwash they are using in order to reduce bias. The researchers will then monitor healing by measuring wound recovery, pain levels, and how easily patients can open their mouths during the first week after surgery.
The main outcome being studied is how well the surgical wound heals after one week. Additional outcomes include the level of pain experienced each day and the degree of mouth opening after surgery.
Study Hypothesis
The study hypothesis is that patients using ORAL7® mouthwash will have similar or better wound healing, less postoperative pain, and improved mouth opening compared to patients using 0.2% chlorhexidine mouthwash after wisdom tooth surgery.
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
This study is a single-blinded, randomized controlled clinical trial designed to evaluate the effects of a natural enzyme-containing mouthwash (ORAL7®) on postoperative outcomes following the surgical removal of impacted mandibular third molars, in comparison with 0.2% chlorhexidine gluconate (CHX) mouthwash.
Postoperative management following third molar surgery typically includes antiseptic mouth rinses to reduce microbial load and support soft tissue healing. While chlorhexidine remains the standard adjunctive mouthwash due to its broad-spectrum antimicrobial activity, its use is associated with well-documented adverse effects, including tooth staining, taste alteration, and potential cytotoxic effects on oral tissues. These limitations have prompted increasing interest in alternative agents that can support oral wound healing while maintaining antimicrobial efficacy.
ORAL7® is an enzyme-based oral rinse formulated to mimic components of the innate salivary defense system. It contains lactoperoxidase, lysozyme, lactoferrin, and glucose oxidase, which collectively contribute to antimicrobial activity through enhancement of the lactoperoxidase-thiocyanate-hydrogen peroxide system. This enzymatic system supports microbial homeostasis, limits pathogenic bacterial growth, and may contribute to a more favorable environment for tissue repair without disrupting normal oral microflora to the same extent as conventional antiseptics.
The biological rationale for this intervention is based on the role of salivary enzymes in regulating inflammation, microbial colonization, and tissue regeneration. Lactoperoxidase generates antimicrobial hypothiocyanite ions, lysozyme disrupts bacterial cell walls and modulates inflammatory activity, lactoferrin regulates iron availability while supporting immune modulation and tissue repair, and glucose oxidase contributes to controlled hydrogen peroxide production that sustains enzymatic antimicrobial activity. Collectively, these mechanisms may influence early wound healing dynamics, postoperative discomfort, and functional recovery.
Eligible participants undergoing surgical extraction of impacted mandibular third molars under local anesthesia will be allocated into either the ORAL7® group or the CHX group using a randomized allocation method with allocation concealment. Postoperative care will be standardized across both groups except for the assigned mouthwash regimen.
Participants will be instructed to use the allocated mouthwash for a fixed period following surgery, and postoperative recovery will be monitored over the first week. Clinical assessments will focus on soft tissue healing status at the surgical site, patient-reported pain intensity, and functional limitation related to mouth opening. These outcomes reflect key domains of postoperative recovery in oral surgery, including tissue repair, inflammation-related discomfort, and functional impairment.
The study is designed to generate comparative clinical evidence regarding whether an enzyme-based oral rinse can provide equivalent or improved postoperative outcomes compared to chlorhexidine, particularly in terms of wound healing quality, pain reduction, and recovery of mandibular function. Findings may contribute to optimizing postoperative oral care protocols and reducing reliance on antiseptic agents with known side-effect profiles.
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
Kelantan
-
Kota Bharu, Kelantan, Malajsie, 16150
- Oral and Maxillofacial Surgery Unit, School of Dental Sciences, Universiti Sains Malaysia
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion Criteria:
- 18 years old and older until required number of samples has been obtained
- Impacted mandibular third molar required bone removal
- Absence of acute infection in impacted mandibular third molar
- Absence of deep caries in the adjacent tooth
- No known medical illness
- No known drug allergy
- Not on medication (prescribed or over the counter)
Exclusion Criteria:
- 1 Mandibular third molar with soft tissue impaction only
- Distoangulated tooth with deep impaction.
- Active smoker
- Pregnant women
- Patients undergoing removal of impacted mandibular third molar due to trauma justification, such as the impacted tooth is at the fractured site.
- Mentally challenged patient
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Trojnásobný
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: ORAL7® Enzyme-Containing Mouthwash Group
ORAL7® Enzyme-Containing Mouthwash Group Participants in this arm will receive ORAL7® mouthwash as the postoperative rinse following surgical removal of impacted mandibular third molars. ORAL7® is an enzyme-based oral rinse containing lactoperoxidase, lysozyme, lactoferrin, and glucose oxidase, which support the natural salivary antimicrobial system. Participants will be instructed to rinse with approximately 10 mL of the mouthwash for 30 seconds, three times daily for 7 days starting on the first postoperative day. |
Enzyme-containing mouthwash used postoperatively after surgical removal of impacted mandibular third molars.
Contains lactoperoxidase, lysozyme, lactoferrin, and glucose oxidase.
Used as a 10 mL rinse for 30 seconds, three times daily for 7 days starting from postoperative day 1.
|
|
Aktivní komparátor: 0.2% Chlorhexidine Gluconate Mouthwash Group
0.2% Chlorhexidine Gluconate Mouthwash Group Participants in this arm will receive 0.2% chlorhexidine gluconate mouthwash as the postoperative rinse following surgical removal of impacted mandibular third molars. Chlorhexidine is a broad-spectrum antiseptic commonly used in oral surgery to reduce microbial load and support wound healing. Participants will be instructed to rinse with approximately 10 mL of the solution for 30 seconds, three times daily for 7 days starting on the first postoperative day. |
Standard antiseptic mouth rinse used following oral surgery.
Participants rinse with 10 mL for 30 seconds, three times daily for 7 days starting from postoperative day 1.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Postoperative Pain Score
Časové okno: Daily from Postoperative Day 1 to Postoperative Day 7
|
Assessment of postoperative pain intensity using the Visual Analogue Scale (VAS) ranging from 0 to 10 following surgical removal of impacted mandibular third molars.
|
Daily from Postoperative Day 1 to Postoperative Day 7
|
|
Landry Wound Healing Index Score
Časové okno: Postoperative Day 7
|
Assessment of postoperative soft tissue healing using the Landry Wound Healing Index following surgical removal of impacted mandibular third molars.
Healing will be evaluated based on tissue color, bleeding on palpation, granulation tissue, incision margin condition, and suppuration.
|
Postoperative Day 7
|
|
Postoperative Mouth Opening
Časové okno: Preoperative baseline and Postoperative Day 7
|
Assessment of postoperative mouth opening measured in millimeters between the maxillary and mandibular incisal reference points following surgical removal of impacted mandibular third molars.
|
Preoperative baseline and Postoperative Day 7
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Analgesic Consumption
Časové okno: Daily from Postoperative Day 1 to Postoperative Day 7
|
Assessment of the total number of analgesic medications consumed following surgical removal of impacted mandibular third molars.
Analgesic use will include prescribed celecoxib and rescue paracetamol intake recorded daily by participants.
|
Daily from Postoperative Day 1 to Postoperative Day 7
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- GAL007-0000000619-M206
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Pooperační bolest
-
Liu JiuhongDokončenoRebound Pain | Lipozomální bupivakainČína
-
University of VirginiaZatím nenabírámeArtroplastika ramene | Interscalene Block | Rebound PainSpojené státy
-
Karaman Training and Research HospitalDokončeno
-
Ajou University School of MedicineNábor
-
Beijing Sport UniversityZatím nenabírámePatellofemoral Pain, PFP
-
Beijing Sport UniversityZatím nenabíráme
-
Istanbul University - CerrahpasaNáborPatellofemoral Pain, PFPTurecko (Türkiye)
-
Pamukkale UniversityZatím nenabírámePatellofemoral Pain, PFPTurecko (Türkiye)
-
Beijing Sport UniversityDokončenoPatellofemoral Pain, PFPČína
-
The First Affiliated Hospital of Xiamen UniversityNáborRebound Pain | Artroskopická operace kolena | OliceridinČína
Klinické studie na ORAL7® Mouthwash
-
Yeh,Shiao FengAktivní, ne nábor
-
ZAINAB MAT YUDINNábor
-
Hospital Universiti Sains MalaysiaDokončenoZánět dásní | Gingivitida vyvolaná plakemMalajsie
-
US Oncology ResearchNovartis PharmaceuticalsDokončenoStomatitida | Orální mukositida | Zhoubný nádor prsu | Novotvar prsuSpojené státy
-
Juravinski Cancer Centre FoundationDokončenoMagic Mouthwash Plus Sucralfate Versus Benzydamin Hydrochlorid pro léčbu radiací vyvolané mukozitidyRakovina hlavy a krku | MukositidaKanada
-
Dong-A ST Co., Ltd.Dokončeno
-
Chung-Ang University Hosptial, Chung-Ang University...NeznámýFunkční dyspepsieKorejská republika
-
Sanofi Pasteur, a Sanofi CompanyDokončenoPertussis | Záškrt | ObrnaSpojené státy
-
Amir AzarpazhoohInstitut Straumann AGDokončeno
-
Novartis PharmaceuticalsDokončenoPlicní onemocnění, chronická obstrukční (CHOPN)Argentina